Rituxan Binding Assays

BioOutsource has extensive experience in the development, optimization and validation of a wide range of different types of binding assays and bioassays and offers GCP, GLP and cGMP testing services in compliance with EMA and FDA guidelines to support the biopharmaceutical industry.
Using this experience, we have created a range of off-the-shelf binding assays, including Rituxan CD20 binding assay, Rituxan C1q binding assay, Rituxan FcRn binding assay and Rituxan Fc-Gamma Receptor binding assays to support clone selection, characterization and biosimilarity studies.

Binding assays are employed to study a number of different features of Rituxan (rituximab) and play a vital role in the development process and characterization and similarity studies, measuring the binding of Rituxan to CD20 as well as C1q, the Fc Gamma Receptors (FcR) and the neonatal Fc Receptor (FcRn). BioOutsource offers a comprehensive range of off-the-shelf generic binding methods to support the characterization of Rituxan (rituximab) and performance of extensive comparability studies:

These methods have been developed using different platforms including ELISA, Electrochemiluminescence (MSD) or Surface Plasmon Resonance (SPR) and can be performed with a variety of different reporting mechanisms including affinity, on and off rates as well as relative binding using a totality of data evaluation approach to provide you with the comprehensive, industry-leading comparability reports to understand all aspects of the performance of your Rituxan molecule.

BioOutsource offers cost-effective solutions to develop custom methods that are not currently in our portfolio – please contact us to find out more.